Preference study about pharmacological treatment for Japanese IPF patients

Preference study about pharmacological treatment for Japanese IPF patients - IPF patient's pharmacological treatment preference study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055763

Enrollment

212

Registered

2024-10-07

Start date

2024-10-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic pulmonary fibrosis: IPF

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients are adults aged 40 years and older, diagnosed IPF by a physician (self-reported). - Provide the evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study (electronic consent).

Exclusion criteria

Exclusion criteria: There are not exclusion criteria in this study.

Design outcomes

Primary

Measure	Time frame
- Pharmacological treatment effect: evaluating the relative importance of treatment attributes to patients with IPF when selecting pharmaceutical treatments - Pharmacological treatment preference: assessing the relative importance of treatment-related side effects (e.g., nausea, diarrhoea, photosensitivity) when selecting pharmaceutical treatments	—

Secondary

Measure	Time frame
- Exploring of IPF patient's unmet medical needs	—

Countries

Japan

Contacts

Public ContactTsuyoshi Ishii

Nippon Boehringer Ingelheim Co., Ltd Medical Affairs Group 2, Medicine Dept. 1, Clinical Development Medical Affairs ILD and Respiratory,

tsuyoshi.ishii@boehringer-ingelheim.com03-6417-2200

Outcome results